Safety Study of an Antipsychotic, Sertindole, to Treat Schizophrenia

H. Lundbeck A/S18 enrolled

Overview

The purpose of this study is to permit the patients with schizophrenia who received Sertindole during a previous randomised trial, study 99824, to continue with this treatment.

Schizophrenia is a disabling and often chronic disorder that may require long-term treatment. This protocol is an extension study of a randomised study comparing the safety of Sertindole versus Risperidone. Patients who were randomised to Sertindole and who completed the previous study have the possibility to receive continued Sertindole treatment in this open one-arm study. Sertindole is generally well tolerated and is approved in the EU, but not yet marketed in France. The follow-up of the patients will be similar to that in the previous study and requires quarterly visits. Patient management reflects routine clinical practice in accordance with the Sertindole label. Any severe safety issue is reported to the company.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Schizophrenia

Interventions

SertindoleDRUG

Flexible dose

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Participation in the previous SCoP study, 99824 * Still fulfils the EU SPC requirements for Sertindole Exclusion Criteria: * Withdrawn before the end of the SCoP study, 99824 * Become homeless * Participation in another clinical trial at the same time * Unlikely to comply with the clinical study protocol or is unsuitable for any reason

Locations (1)

FR002

Allonnes, France

Outcomes

Primary Outcomes

All serious adverse events reported; visits scheduled every 3 months

Time frame: Every 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.